Hypoglycemia, Treatment Discontinuation, and Costs in Patients with Type 2 Diabetes Mellitus on Oral Antidiabetic Drugs

References

• . Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, 2011. http://www.cdc.gov/diabetes/pubs/factsheet11.htm. Accessed February 14, 2011
   Google Scholar
• . International Diabetes Foundation. “Diabetes Atlas” Web site. 2010. http://www.diabetesatlas.org. Accessed February 14, 2010
   Google Scholar
• . American Diabetes Association. “Diabetes Basics” Web site. 2010. http://www.diabetes.org/diabetes-basics. Accessed February 14, 2010
   Google Scholar
• . Rodbard HW, Jellinger PS, Davidson JA,. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540–559
   PubMed Web of Science ®Google Scholar
• . Pratley RE, Salsali A. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Curr Med Res Opin. 2007;23(4): 919–931
   PubMed Web of Science ®Google Scholar
• . Zarowitz BJ, Conner C. The intersection of safety and adherence: new incretin-based therapies in patients with type 2 diabetes mellitus. Pharmacotherapy. 2009;29(12 pt 2):55S–67S
   PubMed Web of Science ®Google Scholar
• . Amiel SA, Dixon SA, Mann R, Jameson K. Hypoglycaemia in type 2 diabetes. Diabet Med. 2008;25(3):245–254
   PubMed Web of Science ®Google Scholar
• . Cryer PE, Axelrod L, Grossman AB,. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2009;94(3):709–728
   PubMed Web of Science ®Google Scholar
• . UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;50(6):1140–1147
   PubMed Web of Science ®Google Scholar
• . Guisasola F, Povedano S, Krishnarajah G,. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. Diabetes Obes Metab. 2008; 10( suppl 1):25–32
   PubMed Web of Science ®Google Scholar
• . Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, Byington RP, et al.Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24): 2545–2559
   PubMed Web of Science ®Google Scholar
• . Bonds DE, Miller ME, Bergenstal RM,. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010;340:b4909
   PubMed Web of Science ®Google Scholar
• . Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA. 2009;301(15):1565–1572
   PubMed Web of Science ®Google Scholar
• . Pollack MF, Purayidathil FW, Bolge SC, Williams SA. Patient-reported tolerability issues with oral antidiabetic agents: association with adherence; treatment satisfaction and health-related quality of life. Diabetes Res Clin Pract. 2010;87(2):204–210
   PubMed Web of Science ®Google Scholar
• . Rozenfeld Y, Hunt JS, Plauschinat C, Wong KS. Oral antidiabetic medication adherence and glycemic control in managed care. Am J Manag Care. 2008;14(2):71–75
   PubMed Web of Science ®Google Scholar
• . Ginde AA, Espinola JA, Camargo CA Jr. Trends and disparities in U.S. emergency department visits for hypoglycemia, 1993–2005. Diabetes Care. 2008;31(3):511–513
   PubMed Web of Science ®Google Scholar
• . Hammer M, Lammert M, Mejías SM,. Costs of managing severe hypoglycaemia in three European countries. J Med Econ. 2009;12(4): 281–290
   PubMedGoogle Scholar
• . Fabunmi R, Nielsen L, Quimbo R,. Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine. Curr Med Res Opin. 2009;25(3):777–786
   PubMed Web of Science ®Google Scholar
• . Cobden D, Lee W, Balu S,. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus. Pharmacotherapy. 2007; 27(7):948–962
   PubMed Web of Science ®Google Scholar
• . Lee W, Balu S, Cobden D,. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clinical Therapeutics. 2006;28(10): 1712–1725
   PubMed Web of Science ®Google Scholar
• . Bullano M, Al–Zakwani I, Fisher M,. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products. Curr Med Res Opin. 2005;21(2):291–298
   PubMed Web of Science ®Google Scholar
• . Holstein A, Plaschke A, Egberts EH. Incidence and costs of severe hypoglycemia. Diabetes Care. 2002;25(11):2109–2110
   PubMed Web of Science ®Google Scholar
• . Valensi P, Benroubi M, Borzi V,. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study. Int J Clin Pract. 2009;63(3):322–531
   Web of Science ®Google Scholar
• . UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–853
   PubMed Web of Science ®Google Scholar
• . Skyler JS, Bergenstal R, Bonow RO,; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a Scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009;32(1):187–192
   PubMed Web of Science ®Google Scholar